Literature DB >> 15906073

Ocular manifestations in congenital toxoplasmosis.

Laurent Kodjikian1, Martine Wallon, Jacques Fleury, Philippe Denis, Christine Binquet, François Peyron, Justus G Garweg.   

Abstract

BACKGROUND: Retinochoroiditis is the most common ocular manifestation of congenital toxoplasmosis, but other associated ophthalmological pathologies can also occur. The aim of this study was to determine the nature of the latter in treated cases of the disease and to assess their impact on visual function.
METHODS: Four hundred and thirty consecutive children with serologically confirmed congenital toxoplasmosis were included in this study. Data were prospectively collected using standardized ophthalmological assessment forms. The presence of retinochoroiditis and of associated pathologies was ascertained, and their impact on visual function was assessed.
RESULTS: After a median follow-up of 12 years [range 0.6-26 years], 130 children manifested retinochoroiditis. We detected 22 foci of retinochoroiditis at birth and 264 additional ones during the follow-up period. Of these, 48 (17%) were active when first diagnosed. Twenty-five of the 130 children (19%) had other associated ocular pathologies. Of these, 21 (16%) had a strabismus, which was due to macular lesions in 86% of the cases; 7 (5.4%) presented with unilateral microphthalmia, and 4 (3%) with cataracts. Most of these events were detected after the onset of retinochoroiditis. None of the children presented with ocular involvement in the absence of chorioretinal lesions. Macular lesions occurred more frequently in children with associated pathologies (p<0.0001), and associated pathologies were likewise more common in individuals with macular lesions (p=0.0003). Visual impairment occurred in 31/130 cases, and in all but 3 of these eyes it was due not to an associated pathology but to macular retinochoroiditis.
CONCLUSIONS: At the end of the follow-up period, ocular involvement existed in 30% of the treated children with congenital toxoplasmosis. Associated eye pathologies were manifested less frequently than anticipated. They may occur later in life and are an indirect marker of the severity of congenital toxoplasmosis, but they do not have a direct impact on visual acuity. The overall functional prognosis of congenital toxoplasmosis is better than would be expected on the basis of literature findings, with only 2 of the 130 children suffering bilateral visual impairment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906073     DOI: 10.1007/s00417-005-1164-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  21 in total

1.  Diagnosis of congenital toxoplasmosis at birth: what is the value of testing for IgM and IgA?

Authors:  M Wallon; D Dunn; D Slimani; V Girault; F Gay-Andrieu; F Peyron
Journal:  Eur J Pediatr       Date:  1999-08       Impact factor: 3.183

2.  Atypical anterior optic neuropathy caused by toxoplasmosis.

Authors:  Alice Song; Ingrid U Scott; Janet L Davis; Byron L Lam
Journal:  Am J Ophthalmol       Date:  2002-01       Impact factor: 5.258

3.  Baltimore Vision Screening Project.

Authors:  M W Preslan; A Novak
Journal:  Ophthalmology       Date:  1996-01       Impact factor: 12.079

4.  Ophthalmological findings in children with congenital toxoplasmosis. Report from a Swedish prospective screening study of congenital toxoplasmosis with two years of follow-up.

Authors:  K T Fahnehjelm; G Malm; J Ygge; M L Engman; E Maly; B Evengård
Journal:  Acta Ophthalmol Scand       Date:  2000-10

5.  Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year.

Authors:  W Foulon; I Villena; B Stray-Pedersen; A Decoster; M Lappalainen; J M Pinon; P A Jenum; K Hedman; A Naessens
Journal:  Am J Obstet Gynecol       Date:  1999-02       Impact factor: 8.661

6.  Presumed toxoplasmic papillitis.

Authors:  J C Folk; L A Lobes
Journal:  Ophthalmology       Date:  1984-01       Impact factor: 12.079

7.  Congenital toxoplasmosis: eye manifestations in infants and children.

Authors:  K Vutova; Z Peicheva; A Popova; V Markova; N Mincheva; T Todorov
Journal:  Ann Trop Paediatr       Date:  2002-09

8.  Eye manifestations of congenital toxoplasmosis.

Authors:  M B Mets; E Holfels; K M Boyer; C N Swisher; N Roizen; L Stein; M Stein; J Hopkins; S Withers; D Mack; R Luciano; D Patel; J S Remington; P Meier; R McLeod
Journal:  Am J Ophthalmol       Date:  1996-09       Impact factor: 5.258

9.  Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis.

Authors:  C Binquet; M Wallon; C Quantin; L Kodjikian; J Garweg; J Fleury; F Peyron; M Abrahamowicz
Journal:  Epidemiol Infect       Date:  2003-12       Impact factor: 2.451

10.  Long term ocular and neurological involvement in severe congenital toxoplasmosis.

Authors:  C Meenken; J Assies; O van Nieuwenhuizen; W G Holwerda-van der Maat; M J van Schooneveld; W J Delleman; G Kinds; A Rothova
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

View more
  14 in total

1.  MARveling at parasite invasion.

Authors:  Kristin M Hager; Vern B Carruthers
Journal:  Trends Parasitol       Date:  2008-01-18

2.  Activation of toxoplasma retinochoroiditis during pregnancy and evaluation of ocular findings in newborns.

Authors:  Fatih Mehmet Türkcü; Alparslan Şahin; Harun Yüksel; Yasin Çınar; Kürşat Cingü; Suat Altındağ; Özcan Deveci; Zeynep Özkurt; İhsan Çaça
Journal:  Int Ophthalmol       Date:  2016-08-01       Impact factor: 2.031

3.  Peptide microarray analysis of in silico-predicted epitopes for serological diagnosis of Toxoplasma gondii infection in humans.

Authors:  Pavlo Maksimov; Johannes Zerweck; Aline Maksimov; Andrea Hotop; Uwe Gross; Uwe Pleyer; Katrin Spekker; Walter Däubener; Sandra Werdermann; Olaf Niederstrasser; Eckhardt Petri; Marc Mertens; Rainer G Ulrich; Franz J Conraths; Gereon Schares
Journal:  Clin Vaccine Immunol       Date:  2012-04-11

Review 4.  Schizophrenia and Infections: The Eyes Have It.

Authors:  E Fuller Torrey; Robert H Yolken
Journal:  Schizophr Bull       Date:  2017-03-01       Impact factor: 9.306

5.  Effect of hyperprolactinaemia on Toxoplasma gondii prevalence in humans.

Authors:  Katarzyna Dzitko; Sebastian Malicki; Jan Komorowski
Journal:  Parasitol Res       Date:  2007-12-20       Impact factor: 2.289

Review 6.  Why prevent, diagnose and treat congenital toxoplasmosis?

Authors:  Rima McLeod; Francois Kieffer; Mari Sautter; Tiffany Hosten; Herve Pelloux
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

7.  Autoantibodies Against Ubiquitous and Confined Antigens in Patients With Ocular, Neuro-Ophthalmic and Congenital Cerebral Toxoplasmosis.

Authors:  Monica Goldberg-Murow; Carlos Cedillo-Peláez; Luz Elena Concha-Del-Río; Rashel Cheja-Kalb; María José Salgar-Henao; Eduardo Orozco-Velasco; Héctor Luna-Pastén; Fernando Gómez-Chávez; Antonio Ibarra; Dolores Correa
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

8.  Maternal serologic screening to prevent congenital toxoplasmosis: a decision-analytic economic model.

Authors:  Eileen Stillwaggon; Christopher S Carrier; Mari Sautter; Rima McLeod
Journal:  PLoS Negl Trop Dis       Date:  2011-09-27

9.  Changes in the expression of human cell division autoantigen-1 influence Toxoplasma gondii growth and development.

Authors:  Jay R Radke; Robert G Donald; Amy Eibs; Maria E Jerome; Michael S Behnke; Paul Liberator; Michael W White
Journal:  PLoS Pathog       Date:  2006-10       Impact factor: 6.823

10.  Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis.

Authors:  Sarra E Jamieson; Lee-Anne de Roubaix; Mario Cortina-Borja; Hooi Kuan Tan; Ernest J Mui; Heather J Cordell; Michael J Kirisits; E Nancy Miller; Christopher S Peacock; Aubrey C Hargrave; Jessica J Coyne; Kenneth Boyer; Marie-Hélène Bessieres; Wilma Buffolano; Nicole Ferret; Jacqueline Franck; François Kieffer; Paul Meier; Dorota E Nowakowska; Malgorzata Paul; François Peyron; Babill Stray-Pedersen; Andrea-Romana Prusa; Philippe Thulliez; Martine Wallon; Eskild Petersen; Rima McLeod; Ruth E Gilbert; Jenefer M Blackwell
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.